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The role of intestinal eosinophils in immune homeo-
stasis is enigmatic and the molecular signals that
drive them from protective to tissue damaging are
unknown. Most commonly associated with Th2
cell-mediated diseases, we describe a role for eo-
sinophils as crucial effectors of the interleukin-23
(IL-23)-granulocyte macrophage colony-stimulating
factor (GM-CSF) axis in colitis. Chronic intestinal
inflammation was characterized by increased bone
marrow eosinopoiesis and accumulation of acti-
vated intestinal eosinophils. IL-5 blockade or eo-
sinophil depletion ameliorated colitis, implicating
eosinophils in disease pathogenesis. GM-CSF was
a potent activator of eosinophil effector functions
and intestinal accumulation, and GM-CSF blockade
inhibited chronic colitis. By contrast neutrophil accu-
mulation was GM-CSF independent and dispensable
for colitis. In addition to TNF secretion, release of
eosinophil peroxidase promoted colitis identifying
direct tissue-toxic mechanisms. Thus, eosinophils
are key perpetrators of chronic inflammation and tis-
sue damage in IL-23-mediated immune diseases
and it suggests the GM-CSF-eosinophil axis as an
attractive therapeutic target.
INTRODUCTION
Chronic intestinal inflammation is characterized by dysregulated
T helper 1 (Th1) and Th17 cell and innate lymphoid cell responses
with excessive production of inflammatory cytokines (Maloy
and Powrie, 2011), leading to increased production of granulo-
cyte-monocyte progenitors (GMPs) and accumulation of inflam-matory myeloid cells in the target tissue (Griseri et al., 2012).
Previously we described an interleukin-23 (IL-23)-granulocyte
macrophage colony-stimulating factor (GM-CSF) axis as a
key driver of dysregulated hematopoiesis in colitis (Griseri
et al., 2012); however, the relative contribution of distinct innate
effector cells downstream of this pathway remains unknown.
Neutrophils are considered a major culprit in IL-23-Th17-cell-
type-mediated tissue damage (Chin and Parkos, 2006; Nathan,
2006), while the pathogenic role of eosinophils has primarily
been established for Th2 cell-mediated conditions such allergic
skin and lung disease (Rosenberg et al., 2013).
Eosinophils, which arise from GMPs through an eosinophil
progenitor (EoP) intermediate (Iwasaki et al., 2005), are rare in
the blood but more abundant in tissues such as the gastrointes-
tinal tract, although their contribution to intestinal homeostasis
remains enigmatic (Kita, 2011; Mishra et al., 1999). Beyond their
role in Th2 cell immunity, eosinophil secrete various inflamma-
tory mediators (e.g., TNF, IL-13, CXCL1) and have been impli-
cated in activation of dendritic cells (DCs) and neutrophils
(Rosenberg et al., 2013). They can also release anti-microbial
compounds toxic for viruses and bacteria and promote the
survival of immunoglobulin A (IgA)-secreting plasma cells in the
intestine, suggesting a possible anti-microbial function (Chu
et al., 2014; Rosenberg et al., 2013).
A dysregulated eosinophil response can cause immune pa-
thology, and this is most evident in atopic diseases such as
asthma and eczema, Th2 cell-mediated eosinophilic esophagi-
tis, and hypereosinophilic syndrome (Fulkerson and Rothenberg,
2013). However, the molecular signals that drive eosinophils
from protective to tissue damaging cells are ill-defined and
require further characterization. Similar to neutrophils, eosino-
phils produce a range of cytotoxic mediators; matrix metallo-
proteinases and reactive oxygen species, as well as specific
proteins such as eosinophil peroxidase (EPO) and eosinophil
cationic protein (ECP) (Fulkerson and Rothenberg, 2013). These
molecules are toxic for invading microorganisms but can also
lead to collateral damage to host tissues including the intestinalImmunity 43, 187–199, July 21, 2015 ª2015 The Authors 187
epithelium (Fulkerson and Rothenberg, 2013; Plager et al., 2009).
Indeed, intestinal eosinophil accumulation has been implicated
in the pathogenesis of a chemically induced model of acute
colonic injury (Forbes et al., 2004) and increased eosinophil
numbers and activation has been reported in inflammatory
bowel disease (IBD) (Ahrens et al., 2008; Saitoh et al., 1999).
However, despite their abundance in the intestine, the regulation
of eosinophils by colitogenic cytokines and their functional role in
chronic intestinal inflammation is not known.
Our previous work identified IL-23-driven GM-CSF as a key
mediator of chronic inflammation in T cell transfer colitis. GM-
CSF promoted intestinal inflammation at several levels, including
skewing of hematopoiesis toward granulo-monocytopoiesis and
accumulation of highly proliferative GMPs in the intestine (Griseri
et al., 2012). Using experimental models of chronic colitis, we
now show that GM-CSF promoted IL-23-driven intestinal inflam-
mation through local accumulation of activated eosinophils and
potentiation of their effector functions. In addition, it also pro-
moted bone marrow (BM) eosinopoiesis in synergy with IL-5.
Because IL-23 is a well-known driver of the Th17 cell response,
these results provide evidence of a link between the Th17-cell-
type response and eosinophils in intestinal inflammation and
suggest that targeting the GM-CSF-eosinophil axis might have
therapeutic utility in some forms of IBD.
RESULTS
Chronic Colitis Is Associated with High Numbers of
Activated Eosinophils
To investigate the relative contribution of granulocyte subsets to
chronic intestinal inflammation, we used a well-characterized
T cell transfer model of IL-23 driven colitis. In this model, chronic
colitis develops 6 weeks after transfer of T cells into Rag1/
mice and is accompanied by increased granulopoiesis (Griseri
et al., 2012). Standard markers were used to discriminate eosin-
ophils (Siglec-F+Gr1int) from Siglec-FGr1hi neutrophils (Dyer
et al., 2011; Zhang et al., 2004). We also used the level of expres-
sion of Siglec-F as a measure of eosinophil activation. Thus,
Siglec-Fint cells are immature or resting eosinophils that reside
in lymphoid organs and in uninflamed tissues, whereas Siglec-Fhi
cells are mature or activated eosinophils mostly found in extra-
lymphoid tissues and increased during inflammation (Rose
et al., 2010; Voehringer et al., 2007). In chronic colitis, we found
both populations among colonic lamina propria leukocytes
(cLPL), with high granularity (SSChi) and expression of the eo-
taxin receptor CCR3 confirming them as eosinophils (Figures
1A and S1A). Percentages of Siglec-Fhi eosinophils were as
high as those of neutrophils in the inflamed intestine, both of
which were 2-fold increased in colitic compared to control
Rag1/ mice. This increase was equivalent to a 40-fold in-
crease in absolute numbers (Figures 1A and 1B). The abundance
of intestinal eosinophils was confirmed in situ, with a high density
of Siglec-F+ cells observed in inflamed colons (Figure S1E).
IL-23-deficient Rag1/ mice, which only develop mild colitis
after T cell transfer (Hue et al., 2006), had a reduced absolute
number and percentage of eosinophils among CD45+ leuko-
cytes compared to colitic IL-23 competent mice, suggesting a
link between intestinal eosinophil accumulation and IL-23-driven
inflammation (Figure S1B).188 Immunity 43, 187–199, July 21, 2015 ª2015 The AuthorsEosinophils in the inflamed intestine showed increased activa-
tion based on a number of parameters. First the majority express
high amounts of Siglec-F (Figure 1C), a phenotype associated
with activation in inflammatory lung disease (Ohnmacht et al.,
2007; Rose et al., 2010).Consistentwith their increasedactivation
state, Siglec-Fhi eosinophils in the inflamed intestine also ex-
pressed higher amounts of other eosinophil activation markers
such as CD11b, IL-33R, and Gr1 (Figure 1C) (Kita, 2011; Master-
sonet al., 2014;Stolarski et al., 2010). Theseactivatedeosinophils
in colitis also expressed the degranulation marker CD63 (Verjan
Garcia et al., 2011). Such cells were 1.7-fold higher in the colon
of coliticmicecompared tocontrolswitha60-fold increase in total
numbers (Figure 1D). Finally, while resting Siglec-Fint eosinophils
in the BMand spleen secreted negligible amounts of TNF, 14%of
eosinophils in the inflamed colon were positive for TNF (Fig-
ure S1D), a crucial colitogenic cytokine (Maloy and Powrie, 2011).
Interestingly, protection from colitis by co-transfer of Foxp3+
regulatory T (Treg) cells with colitogenic CD4+ T cells reduced
not only cLPL neutrophil numbers but also eosinophil accumula-
tion and activation, indicating similar inhibitory effects of Treg
cells on neutrophils and eosinophils in this model (Figure S1C).
Taken together, these data show that eosinophils are a major
constituent of the IL-23-driven intestinal inflammatory network
(4 to 12% of total cLPL in colitis, Figure 1B). Although a
predominant population of eosinophils in the normal intestinal
mucosa had a resting Siglec-Fint phenotype, a shift toward an
activated Siglec-Fhi population with signs of degranulation
occurred during chronic intestinal inflammation.
Increased Eosinopoiesis Is a Feature of Chronic Colitis
Aswe observed sustained accumulation of eosinophils in chronic
intestinal inflammation, we next sought to investigate the role of
eosinopoiesis in this process. Eosinophils can increase their life-
span from a few days to a few weeks within inflamed tissues
(Geering et al., 2013), therefore we could not exclude that the
abundant stock of preformedeosinophils in theBM (Figure 2B) fu-
elled tissue accumulation without major changes in eosinopoie-
sis. We first examined this in T cell transfer colitis and found that
a striking 3.5-fold expansion of EoPs correlatedwith a substantial
increaseof eosinophils in theBMof coliticmice compared to con-
trols (Figures 2A and 2B). There was also a 2-fold increase in the
percentageofBMeosinophilspositive for thegut-hominga4b7 in-
tegrin (Figure 2C). Consistent with these results, 7% of CD4+
T cells in the inflamed intestine expressed the eosinopoietin IL-5
(Figure S2A). GM-CSF, which can act in synergywith IL-5 to stim-
ulate eosinopoiesis (Tomonagaet al., 1986),wasalso increased in
the inflamed colon compared to controls (Figure S2B) and40%
of CD4+ T cells were GM-CSF+ in colitis (Figure S2A).
Next we investigated eosinopoiesis in a lymphocyte replete
model of colitis to ensure our results were not a consequence of
altered myelopoiesis in Rag1/ hosts. For this we used a well-
described model of colitis following Helicobacter hepaticus (Hh)
infection and concomitant blockade of the IL-10-IL-10R pathway
(Kullberg et al., 2006). In thismodel, therewas a similar increase in
EoPs and BM eosinophils, as well as accumulation of activated
TNF-secreting eosinophils in the colon (Figures 2D, 2E, and S2D).
Mature granulocytes in peripheral tissue are described as
post-mitotic (Geering et al., 2013) and indeed eosinophils that
accumulated in the inflamed colon stained negative for BrdU
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Figure 1. Chronic Colitis Is Associated with an Increase in Activated Eosinophils
Colitis was induced by transfer of naive CD4+CD45RBhi T cells into C57BL/6.Rag1/mice. Mice were analyzed 6 to 8 weeks after transfer (colitic) and compared
with untransferred Rag1/ mice (control).
(A) Representative staining of resting eosinophils (Gr1intSiglec-FintSSChi), activated eosinophils (Gr1intSiglec-FhiSSChi), neutrophils (Gr1hiSiglec-FSSCint), and
monocytes or macrophages (Gr1intSiglecFSSClo/int) from colonic lamina propria leukocytes (cLPL). Frequencies and MFI are indicated.
(B) Frequencies and absolute numbers of neutrophils and Siglec-Fhi eosinophils (termed ‘‘eosinophils’’ thereafter).
(C) Representative Gr1 and Siglec-F staining from cLPL (left). Ratio of activated/resting (SigFhi/SigFint) eosinophils in cLPL (middle). CD11b and Gr1 MFI of
colonic eosinophils in colitis and frequencies of IL-33Rhi eosinophils (right).
(D) Representative CD63 staining, frequencies, and absolute numbers of CD63+Siglec-Fhi eosinophils (±SEM, n = 5 per group). Data points represent individual
mice and bars represent means (B and C). Data are representative of two to three independent experiments. See also Figure S1.after a 16 hr pulse-chase assay, whereas almost half of eosino-
phils developing in the BM had incorporated the dye at this
time (Figure 2F). In contrast, BrdU+ eosinophils appeared in the
intestine only 2–3 days after initial BrdU pulsing (Figure 2F), sug-
gesting that the increase in colonic eosinophils is supported by
sustained BM eosinopoiesis.
Thus, the large accumulation of eosinophils in the inflamed in-
testine was supported by a significant increase in eosinopoiesis,
giving rise in the BM to newly formed eosinophils that were pref-
erentially tagged for intestinal migration.Eosinophilia in Colitis Is Mediated by GM-CSF-R-b
Signaling
GM-CSF can directly stimulate eosinopoiesis and eosinophil
survival (Geering et al., 2013; Tomonaga et al., 1986). To test
whether the GM-CSF-eosinophil pathway is pathological in
colitis in a lymphocyte-replete setting, we turned to the Hh
and anti-IL-10R colitis model described above. Lack of a
GM-CSF-Rb signal in Csf2rb/ mice reduced EoP and eosin-
ophil increases in the BM in this chronic model of colitis
(Figure 3A). A change in eosinopoiesis was accompanied byImmunity 43, 187–199, July 21, 2015 ª2015 The Authors 189
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Figure 2. Increased Eosinopoiesis in the Bone Marrow of Colitic Mice
(A–C) Colitis was induced by transfer of naive T cells into C57BL/6.Rag1/ mice. Mice were sacrificed 6 to 8 weeks after transfer (colitic) and compared to
untransferred controls. (A) Representative staining and frequencies of LinCD34+Sca-1c-KitintIL-5Ra+ eosinophil progenitors (EoPs) among BM cells.
(B) Representative staining, frequencies, and absolute numbers of eosinophils in the BM. (C) Representative staining and frequencies of a4b7 integrin and eotaxin
receptor-CCR3-positive eosinophils in the BM.
(D–F) Colitis was induced in C57BL/6 WT mice by infection with H.hepaticus (Hh) combined with anti-IL-10R treatment for 2 to 3 weeks (Hh+anti-IL-10R), which
were compared to a group of uninfected and untreated mice (‘‘uninfected,’’ no anti-IL10R treatment). (D) Frequencies of eosinophil EoPs and eosinophils among
BM cells. (E) Frequencies and absolute numbers of eosinophils among cLPL. (F) Representative staining of BrdU incorporation by eosinophil in the BM and colon
at 16 and 84 hr after initial BrdU pulsing. Frequencies ± SD are indicated (nR 4). Data are representative of two independent experiments. See also Figure S2.a 90% decrease in percentages of intestinal eosinophils in
Csf2rb/ versus WT infected mice, whereas percentages of
neutrophils and CD4+ T cells were similar (Figures 3C and
S2C). This alteration in the composition of the cellular infiltrate
correlated with a significantly reduced colitis score in Csf2rb/
compared to WT mice (Figure 3B) and a decrease in the ratio of
activated to resting eosinophils in the intestine (Figure 3C). It
was notable that the decrease in intestinal eosinophils in
Csf2rb/ mice occurred at steady state, whereas the lack of
IL-23R signaling had no effect on the accumulation of eosino-
phils in the normal intestine (Figure S3A). Next we utilized
mixed WT and Csf2rb/ BM chimeras to distinguish cell-
intrinsic from non-cell-autonomous secondary effects. While
cell-intrinsic GM-CSF-Rb signaling was not required for accu-
mulation of neutrophils and monocytes in the inflamed intes-
tine, cell autonomous GM-CSF-Rb signaling was required for
eosinophil accumulation in colitis (Figure 3D).190 Immunity 43, 187–199, July 21, 2015 ª2015 The AuthorsTogether, these data indicate that GM-CSF-Rb chain signaling
promotes eosinophilia and colitis and differentially regulates
the accumulation of neutrophils and eosinophils in the inflamed
intestine.
Eosinophil Depletion but Not Neutrophil Depletion
Ameliorates Colitis
Because the lack of colitis observed inCsf2rb/mice correlated
with a decrease in the frequency of eosinophils, but not neutro-
phils, we next investigated the relative contribution of these
distinct innate effectors to the pathogenesis of colitis. We em-
ployed two strategies to deplete eosinophils, either blockade
of the eosinopoietin IL-5 (Kouro and Takatsu, 2009) or anti-
body-mediated depletion of Siglec-F+ cells. In the presence of
IL-10R blockade, Hh infected mice treated with anti-IL-5 had a
50% reduction in total cLPL compared to isotype treated con-
trols (data not shown) and an 87% decrease in the percentage
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Figure 3. A GM-CSFR-b Chain Signal Drives Eosinophil But Not Neutrophil Accumulation and Is Required for the Development of Colitis
Colitis was induced in C57BL/6 WT mice and Csf2rb/mice (A–C) or mixed BM chimeric mice (D) upon infection with Hh combined with anti-IL-10R treatment.
Mice were analyzed 2–3 weeks following induction of colitis (A–D). (A) Representative staining of EoPs and frequencies of eosinophils among total BM cells.
(B) Representative photomicrographs of mid-colon sections (magnification 1003) and colitis scores. (C) Representative staining and frequencies of neutrophils
and eosinophils among total cLPL and ratio of activated/resting eosinophils. Data points represent individual mice and bars represent means (A–C).
(D) Representative staining of cLPL from a mixed BM chimera (WT CD45.1 and Csf2rb/ CD45.2). Frequencies ± SD (n = 6), gating and statistics are indicated.
Data are representative of at least two independent experiments. See also Figure S3.of Siglec-Fhi eosinophils (Figure 4A). Most importantly, this was
accompanied by a significant reduction in colitis severity
compared to isotype treated controls (Figure 4B).
The IL-5R is constitutively expressed by eosinophils but also
by some B cell subsets (Kouro and Takatsu, 2009). Therefore,
to further increase the specificity of treatment, we used an
anti-Siglec-F depletion approach shown to selectively elimi-
nate eosinophils (Chu et al., 2014; Zimmermann et al., 2008).
Although alveolar macrophages in the lung express Siglec-F,
intestinal and peritoneal macrophages do not and are there-
fore not affected by anti-Siglec-F depletion (Feng and Mao,2012; Mowat and Bain, 2011). Treatment with anti-mouse
Siglec-F immune serum reduced colitis severity to the same
extent as IL-5 blockade (Figure 4D). This treatment regimen
led to an 85% decrease of eosinophils based on reduced
CD11b+CCR3+SSChi cells in the colon of anti-Siglec-F versus
pre-immune serum treated mice (Figure 4C), whereas there
was only a 28% reduction in the percentage of colonic neu-
trophils (Figure 4E). The small reduction in neutrophils was
most likely secondary to reduced overall inflammation,
because uninfected mice treated with anti-Siglec-F serum
did not display a decrease in neutrophils or any leukocyteImmunity 43, 187–199, July 21, 2015 ª2015 The Authors 191
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Figure 4. Eosinophil Depletion But Not
Neutrophil Depletion Ameliorates Colitis
WT mice were infected with Hh combined with
anti-IL-10R treatment and analyzed 2–3 weeks
later. Mice received either 2 weekly injections
of anti-IL-5 or isotype control mAbs (A and B),
or sheep anti-Siglec-F serum or pre-immune
serum (C–E) for eosinophil depletion, or 3 weekly
injections of anti-Ly6G or isotype control for
neutrophil depletion (F). Infected mice were
compared to uninfected and untreated controls
(‘‘uninf’’). (A) Representative staining and fre-
quencies of eosinophils among cLPL. (B) Colitis
score and representative photomicrographs of
mid-colon sections (magnification 100x). (C) FACS
staining of SiglecF+ eosinophils (left) and SSChi
CCR3+ eosinophils (middle) and frequencies of
CD11b+CCR3+SSChi eosinophils among cLPL
(right). (D) Colitis score and representative photo-
micrographs of mid-colon sections (magnification
100x). (E) Frequencies of neutrophils among cLPL.
(F) Colitis score (left), total numbers of cLPL (mid-
dle) and representative staining of neutrophils
among cLPL (right). Data are pooled from (A–E) or
are representative of (F) two independent experi-
ments. See also Figure S4.populations other than eosinophils (Figure S4A). By contrast
with eosinophil-depleting strategies, depletion of neutrophils
with an anti-Ly-6G antibody did not have a significant effect
on colitis (Figures 4F and S4B).
Together these results reveal differential roles for eosinophils
and neutrophils in chronic colitis. While eosinophils play a non-
redundant role in disease, neutrophils are dispensable for the
development of chronic intestinal inflammation.192 Immunity 43, 187–199, July 21, 2015 ª2015 The AuthorsGM-CSF Sustains the Accumulation
of Eosinophils with an Activated
Phenotype in Colitis
In order to further understand the colito-
genic role of GM-CSF, we investigated
whether GM-CSF and IL-5 had differential
effects on eosinophil production and acti-
vation. Because GM-CSF-R and IL-5R
share the same b-receptor subunit (Kouro
and Takatsu, 2009), we tested whether
GM-CSF blockade would reproduce the
decrease in eosinophil activation and
accumulation observed in Csf2rb/
mice. Interestingly, IL-5 and GM-CSF
were produced at steady state by ILCs
but were not increased in lymphocyte-
replete colitis (Figure S5B). By contrast,
GM-CSF production by CD4+ T cells
was increased in the inflamed colon
compared to controls, while percentages
of IL-5 producers were unchanged (Fig-
ure S5A). Accordingly, colonic GM-CSF,
but not IL-5, mRNA and protein levels
were augmented in chronic colitis,
possibly highlighting a more homeostatic
role for IL-5 compared with the more acti-vation-induced functions of GM-CSF (Figure 5A and 5B).
Regarding eosinophil chemoattractants, eotaxin-1 and RANTES
were increased in early and late phases of colitis, respectively
(Figure 5A).
When treated with anti-GM-CSF, Hh infected and anti-IL-
10R-treated mice exhibited significantly reduced colonic infil-
trates and colitis score compared to mice treated with isotype
control (Figure 5C) and displayed a striking 50% decrease in
the frequency and activation status of colonic eosinophils
(Figure 5D). While anti-IL-5 treatment inhibited the general
accumulation of colonic eosinophils (Siglec-Fint and Siglec-Fhi)
(Figures 4A and S5D), GM-CSF blockade only decreased the
most activated population (Figures 5D and S5D) suggesting
a role for GM-CSF in intestinal eosinophil activation in the in-
flamed colon.
Blockade of either GM-CSF or IL-5 led to reductions in the
number of eosinophils in the BM; however, only GM-CSF
blockade inhibited the accumulation of GMPs and downstream
EoPs (Figure 5E). These results indicate that during intestinal
inflammation, GM-CSF sustains eosinophilic granulopoiesis,
whereas IL-5 mediates a more specific function promoting the
terminal differentiation of EoPs into Siglec-F+ cells (Figure 5E).
A differential effect of GM-CSF and IL-5 was also evident on
the ‘‘gut-tagging’’ of newly produced BM eosinophils, as upre-
gulation of a4b7 integrin in colitis was only inhibited by IL-5
blockade (Figure 5F).
Overall, these results highlight the synergy between GM-CSF
and IL-5 in the regulation of eosinopoiesis and reveal the key role
of GM-CSF in driving chronic intestinal inflammation through
accumulation of activated eosinophils in the colon.
GM-CSF Promotes the Effector Functions of Mature
Eosinophils in the Inflamed Intestine
We next sought to characterize further the differential regulation
of eosinophils in the periphery by GM-CSF and IL-5. Both cyto-
kines can promote eosinophil survival (Geering et al., 2013), and
we confirmed this observation in colitis. Annexin-V staining on
freshly isolated peripheral eosinophils was decreased in colitis
and increased in the presence of GM-CSF or IL-5 blockade (Fig-
ure 6A). As GM-CSF production was increased during colitis,
while IL-5 levels stayed constant (Figure 5B), we hypothesized
that GM-CSF would be a key driver of eosinophil effector
functions in the inflamed intestine. Indeed, anti-GM-CSF treat-
ment inhibited the increase in CD11b and increase in side
scatter (correlating with granularity), while IL-5 blockade did
not have a significant effect on these markers of activation (Fig-
ure 6B). In addition, cell-sorted eosinophils exhibited morpho-
logical changes in vitro in the presence of GM-CSF, notably
increased diameter as a sign of activation (Figure 6F). Interest-
ingly CD64 (FcgRI), which is increased on neutrophils in IBD
(Minar et al., 2014), was induced on eosinophils during colitis
in a GM-CSF-dependent but IL-5-independent manner (Fig-
ure 6C). Furthermore, the amount of CD64 was higher on
Siglec-Fhi than Siglec-Fint eosinophils (Figure 6C), consistent
with their more activated status.
Regarding expression of cytokines involved in epithelial
cell dysregulation and damage (Neurath, 2014), intestinal eo-
sinophils expressed higher amounts of Tnf, Il6, and Il13
mRNA in colitis compared to uninflamed controls (Figure 6D).
In vitro analysis of cell-sorted intestinal eosinophils showed
that GM-CSF stimulated Tnf and Il13 mRNA expression,
but had no effect on Il6 (Figure 6E). Altogether, these data
demonstrate that GM-CSF and IL-5 promote the survival of
peripheral eosinophils, but only GM-CSF promotes their acti-
vation and inflammatory cytokine production, revealing one
of the key colitogenic effects of GM-CSF during chronic intes-
tinal inflammation.Eosinophil Peroxidase Activity Promotes Chronic Colitis
Because TNF, IL-6, and IL-13 are expressed by various leuko-
cytes, we decided to investigate whether eosinophil-specific
products could also drive chronic intestinal inflammation. For
this purpose, we tested whether EPO, which is produced exclu-
sively by eosinophils and can be tissue-toxic (Fulkerson and
Rothenberg, 2013), contributed to chronic colitis. EPO levels
and activity in the intestine were greatly increased during chronic
inflammation, confirming substantial eosinophil degranulation. In
addition, a reduction in eosinophil numbers during anti-GM-CSF
or anti-IL-5 treatment was accompanied by a significant
decrease in EPO (Figure 7A). Resorcinol is a potent inhibitor of
EPO leading to decreased anti-bacterial activity of eosinophils
(Ledford et al., 2012). In Hh-induced colitis, daily treatment of
WT mice with resorcinol led to significantly reduced EPO activity
and decreased colitis (Figures 7B and 7C). This was accompa-
nied by decreased markers of colonic inflammation compared
to PBS treated mice, including reduced leukocyte infiltration,
lower neutrophil percentages, and a trend toward reduced
IFN-g+ CD4+ T cells (Figures 7B and 7C). EPO inhibition, how-
ever, did not affect the frequency of eosinophils among cLPL
(Figure 7C), consistent with previous in vivo observations (For-
bes et al., 2004; Ledford et al., 2012).
Overall, the pathogenic effect of uncontrolled accumulation of
activated eosinophils in chronic colitis could be attenuated by
inhibition of EPO, an enzyme well known to mediate oxidative
tissue damage in eosinophil-dependent inflammatory diseases
(Fulkerson and Rothenberg, 2013).
DISCUSSION
Our study newly identifies a GM-CSF-eosinophil axis as a crucial
component of IL-23-driven chronic colitis. Our previous work
described GM-CSF as a pivotal downstream effector of IL-23
in the inflammatory cascade that drives aberrant responses to
commensal microbiota through increases in myelopoiesis in
T cell transfer colitis (Griseri et al., 2012). Neutrophils are widely
accepted as tissue-toxic cells in IL-23-mediated colitis (Chin and
Parkos, 2006; Neurath, 2014). However, our results challenge
this view and indicate a more prominent and unexpected role
for eosinophils in this response. We show a marked accumula-
tion of activated eosinophils in the colon of colitic mice, sup-
ported by increased eosinopoiesis, and a direct colitogenic
role through production of eosinophil peroxidase and inflam-
matory cytokines. Although eosinophils are abundant in the
intestine, their role in chronic intestinal inflammation is rarely
considered. Here we identified GM-CSF as a key molecular
switch diverting eosinophils from a tissue-protective to a tis-
sue-toxic state of activation. These results extend the paradigm
of eosinophil-mediated immune pathology beyond Th2 cell-type
responses to effectors of IL-23-GM-CSF-driven dysregulated
tissue immunity.
GM-CSF is emerging as a central cytokine at the crossroads of
various types of effector T cell responses and can be produced
by Th1 and Th2 cells to stimulate increased myeloid cell activity
(Mosmann and Coffman, 1989). More recently it was shown that
IL-23 stimulated Th17 cells to produce GM-CSF, which was
pathogenic in EAE although its functional role was not estab-
lished (El-Behi et al., 2011). In the inflamed intestine, IL-23Immunity 43, 187–199, July 21, 2015 ª2015 The Authors 193
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Figure 5. Specific Blockade of GM-CSF Decreases Colitis and Eosinophilia
WT mice were infected with Hh combined with anti-IL-10R treatment.
(A) qPCR gene expression from total colonic tissue.
(B) Cytokine expression of colonic explant supernatants cultured for 24 hr and normalized to tissue weight (nR 5 per group).
(C–F) Mice received twoweekly injections of anti-GM-CSF or isotype control mAbs and were analyzed after 2–3 weeks along with unmanipulated controls (uninf).
(C) Colitis score, representative photomicrographs of mid-colon sections (magnification 1003) and absolute numbers of total cLPL. (D) Frequencies of Siglec-Fhi
(legend continued on next page)
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stimulated polyfunctional IFNg+IL-17A+Th cells to produce
GM-CSF, which triggered extramedullary hematopoiesis (Griseri
et al., 2012). In this report, we show that GM-CSF increased
eosinopoiesis and numbers of highly activated eosinophils in
the inflamed intestine. GM-CSF promoted increases in GMPs
and downstream EoPs, which both express GM-CSF-R-a and
b chains (Iwasaki et al., 2005). Increased EoPs have been
observed in Th2 cell-mediated asthma and anti-helminth re-
sponses (Iwasaki et al., 2005; Yang et al., 2011), however, our
study constitutes the first report of chronic EoP accumulation
during IL-23-Th17 cell type-mediated immune disease, extend-
ing our previous observation of dysregulated hematopoiesis in
colitis to the eosinophilic lineage.
IL-5 or GM-CSF blockade resulted in a substantial decrease of
eosinophils in the inflamed intestine, however there weremarked
differences in their action. Although both cytokines promoted
eosinopoiesis during colitis, IL-5 specifically increased the differ-
entiation of EoPs into Siglec-F+ eosinophils and promoted
imprinting of a4b7 integrin expression. However by contrast
with GM-CSF it had no effect on the upstream GMP.
Resident populations of intestinal leukocytes contribute to the
maintenance of basal eosinophil numbers as ILCs constitutively
produce IL-5 in the normal intestine and resident macrophages
express eotaxins (Ahrens et al., 2008; Nussbaum et al., 2013).
However, intestinal IL-5 does not appear to be controlled by
IL-23 because IL-5 expression was not increased in colitis or
reduced in IL-23 deficiency. These results are in contrast to the
findings that IL-23 promoted IL-5 and Th2 responses in asthma
models suggesting differences in IL-5 regulation in distinct tissue
sites (Peng et al., 2010; Wakashin et al., 2008). In contrast with
IL-5, IL-23 increased GM-CSF expression by CD4+ T cells and
ILC in colitis (Griseri et al., 2012 and data not shown), pinpointing
an IL-23-GM-CSF-eosinophil axis in colitis that can boost basal
IL-5 dependent eosinophilia. A recent study showed a role for
eosinophils in maintaining intestinal integrity toward the gut
microbiota through stimulating IgA+ plasma cells and Foxp3+
Treg cells (Chu et al., 2014). Importantly, here we show that
the unchecked production of GM-CSF during chronic colitis is
a key driver of the eosinophil switch from a resident and homeo-
static phenotype (Siglec-Fint) to an over-activated and tissue
toxic phenotype (Siglec-Fhi). Siglec-Fhi eosinophils were also
increased in lung inflammation and were more resistant to
apoptosis than Siglec-Fint eosinophils (Ohnmacht et al., 2007).
Eosinophil activation and cytokine secretion that accompanied
colitis was inhibited by GM-CSF but not IL-5 blockade. Further-
more in vitro, GM-CSF acted directly on eosinophils to induce
production of colitogenic cytokines TNF and IL-13. Together
the data suggest that IL-5 plays a homeostatic role maintaining
basal levels of eosinophils in the intestine, whereas GM-CSF
promotes their activation and deleterious effector functions in
chronic colitis.
It is worth noting that GM-CSF-Rb deficiency did not affect
the percentage of neutrophils in the intestine in colitis and
BM chimera experiments, despite inducing a severe decreaseeosinophils and neutrophils among CD45+ cLPL (left), representative FACS
(E) Representative staining and frequencies of BM granulocyte-monocyte pre
eosinophils among BM cells. (F) Representative staining and frequencies of a4b7
are representative of (E and F) two independent experiments. Error bars represein eosinophil percentages. Thus, GM-CSF is not absolutely
required for the neutrophil increase probably owing to the com-
pensatory role of G-CSF, which is a potent inducer of neutro-
philia (Nathan, 2006) and is increased in T cell transfer colitis
(Griseri et al., 2012). Unexpectedly, while eosinophil depletion
dampened colitis, no such effect was provoked by depletion of
neutrophils, highlighting a dichotomy in the role of these granu-
locyte populations in chronic colitis.
Amelioration of chronic colitis by pharmacological inhibition
of EPO, which is implicated in cytotoxic oxidant generation, pin-
pointed one of the molecular mechanisms by which eosinophils
specifically mediate intestinal damage. This pathway has also
been implicated in the DSSmodel of acute colonic injury (Forbes
et al., 2004), suggesting broad relevance in intestinal damage.
Interestingly, regulation of eosinophils in acute versus chronic
intestinal inflammation is not identical as we found that IL-5
depletion inhibited chronic colitis, whereas IL-5 deficiency had
no significant effect in the DSS model contrary to the protective
effect of eotaxin deficiency (Forbes et al., 2004). This suggests
that in an acute damage model, mobilization of mature eosino-
phils from the BM to intestine is sufficient, whereas sustained
chronic colitis requires IL-5-dependent eosinopoiesis.
In human, treatment of eosinophils with GM-CSF in vitro led to
increased release of EPO and ECP, providing further evidence
that GM-CSF can directly increase the cytotoxic functions of
eosinophils (Pazdrak et al., 2011). Conversely, IL-10 inhibited
LPS-induced TNF release and increased survival of human eo-
sinophils in vitro (Takanaski et al., 1994). Treg cells play an
important role in intestinal homeostasis and suppress colitis in
part via IL-10 (Maloy and Powrie, 2011). We found that Treg
cell-mediated control of colitis correlated with a reduction in
eosinophil accumulation and activation. Based on those results,
it is tempting to speculate that under homeostatic conditions eo-
sinophils in the intestine are hyporesponsive to TLR activation as
a consequence of the IL-10 rich environment (Maloy and Powrie,
2011), which might be over-ridden by sustained increases in
GM-CSF production in chronic inflammation.
There are several reports of increased GM-CSF in Crohn’s
disease (CD) and ulcerative colitis (UC) patients (Ina et al.,
1999; Noguchi et al., 2001), and concomitant Th17 and IL-5
and IL-13 T cell responses have been observed in ileal CD sug-
gesting a more polyfunctional T cell response in certain patients
(Zorzi et al., 2013). However GM-CSF activity is a double-edged
sword and when produced in a controlled fashion plays an
important role in the steady state accumulation of mononuclear
phagocytes and Foxp3+ Treg cells (Mortha et al., 2014) and in
promoting host protective immunity in the gut (Hirata et al.,
2010). Consistent with this, intestinal injury in a DSS model
was exacerbated in Csf2rb/ mice further illustrating differ-
ences in themechanisms of acute and chronic intestinal damage
(Egea et al., 2013). Increased levels of anti-GM-CSF autoanti-
bodies have been observed in pediatric and some forms of adult
CD leading to the idea that GM-CSF is protective in IBD. How-
ever three clinical trials of recombinant GM-CSF administrationstaining (middle) and ratio of activated/resting colonic eosinophils (right).
cursors (GMPs), frequencies of EoPs among LinSca-1c-Kithi cells and of
+ eosinophils and CCR3+ eosinophils in the BM. Data are pooled from (A–D) or
nt SD. See also Figure S5.
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Figure 6. GM-CSF Promotes Colonic Eosinophil Activation and Effector Functions
(A–D) WT mice were infected withHh combined with anti-IL-10R treatment and analyzed after 2–3 weeks along with unmanipulated controls (i.e., uninfected and
untreated: ‘‘Uninf’’). Where indicated, mice received twoweekly injections of anti-GM-CSF, anti-IL-5, or isotype control mAbs. (A) Frequencies and representative
staining of apoptotic Annexin V+ (AnnV) eosinophils among splenocytes. (B) CD11b and SSC MFI of colonic eosinophils. (C) Representative staining and per-
centages of CD64+ cells among colonic eosinophils. (D) Cytokine genes expression profile assessed by qPCR from FACS-sorted eosinophils isolated from the
colon of unmanipulated mice (Uninf) or colitic mice (Hh+anti-IL-10R).
(E and F) FACS-sorted eosinophils isolated from the colon of unmanipulatedmicewere stimulated for 18 hr with IL-5 or a combination of IL-5 andGM-CSF or were
left untreated (ctrl). (E) qPCR analysis of cytokine genes expression after in vitro stimulation. (F) Representative Diff-Quick staining (top) and cell size analysis
(bottom) of eosinophil cytospins after in vitro stimulation. Dots represent individual eosinophils and bars indicate means. Data are representative of at least two
experiments. Error bars represent SD.failed to show demonstrable protective effects (Roth et al.,
2012). It is highly likely that GM-CSF will play both protective
and pathological roles in IBD and that the context in which it is
produced, such as where and for how long, might determine
its ultimate functional role.
Several studies have reported increased eosinophil numbers
and activation in both UC and CD (Ahrens et al., 2008; Saitoh196 Immunity 43, 187–199, July 21, 2015 ª2015 The Authorset al., 1999). ECP was also increased in the faeces of IBD
patients suggesting eosinophil degranulation (Bischoff et al.,
1997). Our results in model systems taken together with an
emerging picture in humans suggest that blockade of the
GM-CSF/eosinophil axis might be a therapeutic target in partic-
ular patient subsets. The fact that sustained depletion of eosin-
ophils in patients with hyper-eosinophilic syndrome treated for
AC
B
Figure 7. Eosinophil Peroxidase Activity Promotes Intestinal Inflammation
WTmice were infected withHh combinedwith anti-IL-10R administration and were either treated with two weekly injections of anti-GM-CSF, anti-IL-5, or isotype
control mAbs (A) or injected daily with Resorcinol or PBS (B and C). Mice were analyzed 2–3 weeks after induction of colitis and compared to uninfected and
untreated controls (Uninf). (A) ELISA of eosinophil peroxidase (EPO) (left) or colorimetric assay of EPO activity (middle) assessed in the supernatants of colonic
explants cultured for 24 hr and normalized to tissue weight (n R 6 per group). (B) Colitis score and absolute numbers of cLPL. (C) Colorimetric assay of EPO
activity assessed on the supernatants of total colonic faeces (n = 5–7, left), frequencies of eosinophils and neutrophils among total cLPL (middle), and per-
centages of IFN-g+ cells among colonic CD4+ T cells (right). Data are pooled from two independent experiments. Error bars represent SD.up to 6 years with anti-IL-5 did not lead to adverse effects
is encouraging for considering this approach in IBD (Gleich
et al., 2013).
EXPERIMENTAL PROCEDURES
Mice
B6.SJL-Cd45.1 mice or C57BL/6 mice: wild-type (WT), Csf2rb/, Il23r/,
Rag1/, or Rag1/Il23p19/ were bred and maintained under specific
pathogen–free conditions in accredited animal facilities at the University
of Oxford. All procedures involving animals were conducted according
to the requirements and with the approval of the UK Home Office Ani-
mals (Scientific Procedures) Acts, 1986. Mice were negative for Helico-
bacter spp. and other known intestinal pathogens and were used when
7–12 weeks old.
Induction of T Cell Transfer Colitis
Naive CD4+CD25CD45RBhi T cells and regulatory CD4+CD25+CD45RBlo
T cells were sorted by flow cytometry from enriched CD4+ single-cell
spleen suspensions (Dynal) to a purity of >99%. For the induction of colitis,
4 3 105 naive T cells were injected intraperitoneally (i.p.) into C57BL/
6.Rag1/ recipients. Where indicated, 2 3 105 protective T reg cells were
co-injected i.p.
Helicobacter hepaticus-Dependent Induction of Colitis
Colitis was induced in WT C57BL/6 mice by infecting with Hh (oral gavage)
on 2 consecutive days with 5 3 107–2 3 108 CFU Hh and i.p. injection of
1 mg 1B1.2 (anti-IL10R) mAb on days 0 and 7 after Hh infection (Buonocore
et al., 2010). Mice were killed 7 days after the last anti-IL10R mAb treatment
(weeks 2–3). Where indicated, mice were i.p. injected two times per week
with 0.4 mg of anti-GM-CSF (MP1-22E9; CSL Ltd) or isotype control
(GL117, rat IgG2a) or 0.5 mg of anti-IL-5 (TRFK5; BioXCell), or three times
per week with 0.25 mg anti-Ly6G (1A8; BioXCell) or isotype control (2A3, rat
IgG2a) starting from the first day of Hh infection. Where indicated, mice
were i.p. injected two times per week with sheep preimmune serum orsheep anti-Siglec-F serum. Where indicated, mice were i.p. injected daily
with Resorcinol (1.25mg/kg) or PBS.
Histological Assessment of Intestinal Inflammation
Proximal, mid-, and distal colon samples were fixed in buffered 10% formalin
solution. 5 mm paraffin embedded sections were cut and stained with hema-
toxylin and eosin and inflammation was scored in a blinded fashion (Buono-
core et al., 2010). In brief, 4 parameters of inflammationwere assessed (scored
0–3): epithelial hyperplasia and goblet cell depletion, leukocyte infiltration in
the lamina propria, area of tissue affected, andmarkers of severe inflammation
such as submucosal inflammation. Aggregate scores were taken for each sec-
tion, to give a total inflammation of 0–12. Colon inflammation scores represent
the average score of the three sections taken.
Leukocytes Isolation
Single cell suspensions were prepared from spleen, MLN, and cLPL as pre-
viously described (Buonocore et al., 2010). In brief, colons were longitudi-
nally opened, cut into 1 cm pieces, and incubated in RPMI 1640 with
10% FCS and 5 mM EDTA at 37C to remove epithelial cells. Tissue
was then digested with 100 U/ml of type VIII collagenase (Sigma) in
complete RPMI medium containing 15cmM HEPES during 1 hr at 37C.
The isolated cells were layered on a 30/40/75% Percoll gradient, which
was centrifuged for 20 min at 600 g, and the 40/75% interface, containing
mostly leukocytes, was recovered. BM cell suspensions were prepared by
flushing the marrow out of femur and tibia and were resuspended in PBS
with 2% BSA.
Flow cytometry and cell sorting, quantitation of gene expression using real-
time PCR, in vitro stimulation assays, EPO Elisa and EPO colorimetric assay,
in vivo BrdU labeling and immunofluorescence were performed as described
in Supplemental Experimental Procedures.
Statistical Analysis
Statistical analysis was performed with Prism 6.0 (GraphPad Software). The
nonparametric Mann-Whitney test was used for all statistical comparisons.
Differences were considered statistically significant when p < 0.05.Immunity 43, 187–199, July 21, 2015 ª2015 The Authors 197
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